AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home hLife Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

Selection and engineering of broad-spectrum antiviral affibody peptides against SARS-CoV-2 variants

Jinlei Yang1,2,#, Min Wang1,2,#, Zhao Chen3,#, Yongqi Li1,2,#, Qi Peng1,2, Jinlong Cheng1,2, Xin Zhao1,2, Jincun Zhao3,4,6,7,8, Christopher John Hipolito5( ), Jianxun Qi1,2( ), Yi Shi1,2,3,4( )
Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
University of Chinese Academy of Sciences, Beijing, China
State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China
Strategic Pandemic Action and Research Center (SPARC), Guangzhou National Laboratory, Guangdong, China
Peptide Core Facility, Transborder Medical Research Center, University of Tsukuba, Ibaraki, Japan
Institute of Infectious Disease, Guangzhou Eighth People’s Hospital of Guangzhou Medical University, Guangdong, China
Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, China
National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Guangdong, China

#These authors contributed equally to this work

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
hLife
Volume 3 Issue 9,
September 2025
Pages 448-451
DOI: 10.1016/j.hlife.2025.04.010

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Yang J, Wang M, Chen Z, et al. Selection and engineering of broad-spectrum antiviral affibody peptides against SARS-CoV-2 variants. hLife, 2025, 3(9): 448-451. https://doi.org/10.1016/j.hlife.2025.04.010

361

Views

3

Crossref
Received: 18 March 2025
Revised: 10 April 2025
Accepted: 28 April 2025
Published: 01 September 2025
© 2025 The Author(s).

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).